These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11394507)

  • 1. Compound A: does it matter?
    Eger EI
    Can J Anaesth; 2001 May; 48(5):427-30. PubMed ID: 11394507
    [No Abstract]   [Full Text] [Related]  

  • 2. Composition of CO(2) absorbents.
    Mazze RI
    Anesth Analg; 2001 May; 92(5):1356-7. PubMed ID: 11323380
    [No Abstract]   [Full Text] [Related]  

  • 3. [The use of lithium hydroxide for carbon dioxide absorption prevents formation of compound A during sevoflurane anesthesia].
    Förster H; Behne M; Warnken UH; Asskali F; Dudziak R
    Anaesthesist; 2000 Feb; 49(2):106-12. PubMed ID: 10756964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sevoflurane degradation by carbon dioxide absorbents may produce more than one nephrotoxic compound in rats.
    Stabernack CR; Eger EI; Warnken UH; Förster H; Hanks DK; Ferrell LD
    Can J Anaesth; 2003 Mar; 50(3):249-52. PubMed ID: 12620947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative differences in the production and toxicity of CF2=BrCl versus CH2F-O-C(=CF2)(CF3) (compound A): the safety of halothane does not indicate the safety of sevoflurane.
    Eger EI; Ionescu P; Laster MJ; Gong D; Weiskopf RB; Kerschmann RL
    Anesth Analg; 1997 Nov; 85(5):1164-70. PubMed ID: 9356119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of compound A and carbon monoxide in circle systems: an in vitro comparison of two carbon dioxide absorbents.
    Struys MM; Bouche MP; Rolly G; Vandevivere YD; Dyzers D; Goeteyn W; Versichelen LF; Van Bocxlaer JF; Mortier EP
    Anaesthesia; 2004 Jun; 59(6):584-9. PubMed ID: 15144299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to a sevoflurane degradation product in the guinea pig following inhalation exposure.
    Zheng XH; Begay C; Lind RC; Gandolfi AJ
    Drug Chem Toxicol; 2001 Nov; 24(4):339-46. PubMed ID: 11665647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compound A and carbon monoxide production from sevoflurane and seven different types of carbon dioxide absorbent in a patient model.
    Keijzer C; Perez RS; de Lange JJ
    Acta Anaesthesiol Scand; 2007 Jan; 51(1):31-7. PubMed ID: 17096668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
    Njoku DB; Pohl LR; Sokoloski EA; Marchick MR; Borkowf CB; Martin JL
    Anesthesiology; 1999 Feb; 90(2):458-69. PubMed ID: 9952153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compound A production from sevoflurane is not less when KOH-free absorbent is used in a closed-circuit lung model system.
    Versichelen L; Bouche MP; Struys M; Van Bocxlaer J; Mortier E; de Leenheer AP; Rolly G
    Br J Anaesth; 2001 Mar; 86(3):345-8. PubMed ID: 11573522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No compound a formation with Superia during minimal-flow sevoflurane anesthesia: a comparison with Sofnolime.
    Bouche MP; Versichelen LF; Struys MM; Van Bocxlaer JF; De Leenheer AP; Mortier EP; Rolly G
    Anesth Analg; 2002 Dec; 95(6):1680-5, table of contents. PubMed ID: 12456439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compound A concentration is decreased by cooling anaesthetic circuit during low-flow sevoflurane anaesthesia.
    Osawa M; Shinomura T
    Can J Anaesth; 1998 Dec; 45(12):1215-8. PubMed ID: 10051944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of compound A under low-flow anesthesia is affected by type of anesthetic machine.
    Yamakage M; Kimura A; Chen X; Tsujiguchi N; Kamada Y; Namiki A
    Can J Anaesth; 2001 May; 48(5):435-8. PubMed ID: 11394509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of four carbon dioxide absorbents in experimental and clinical settings.
    Yamakage M; Takahashi K; Takahashi M; Satoh JI; Namiki A
    Anaesthesia; 2009 Mar; 64(3):287-92. PubMed ID: 19302642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity of halogenated inhalational anaesthetics: fictions and facts.
    Reichle FM; Conzen PF; Peter K
    Eur Surg Res; 2002; 34(1-2):188-95. PubMed ID: 11867922
    [No Abstract]   [Full Text] [Related]  

  • 16. Fate and toxicity of 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A)-derived mercapturates in male, Fischer 344 rats.
    Uttamsingh V; Iyer RA; Baggs RB; Anders MW
    Anesthesiology; 1998 Nov; 89(5):1174-83. PubMed ID: 9822006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cysteine conjugate beta-lyase and compound A nephrotoxicity: minimal evidence for an association.
    Njoku DB; Martin JL; Pohl LR
    Anesthesiology; 1999 Mar; 90(3):921-2. PubMed ID: 10078700
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat.
    Martin JL; Laster MJ; Kandel L; Kerschmann RL; Reed GF; Eger EI
    Anesth Analg; 1996 Apr; 82(4):770-4. PubMed ID: 8615496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleeping with uncertainty: anesthetics and desiccated absorbent.
    Woehlck HJ
    Anesthesiology; 2004 Aug; 101(2):276-8. PubMed ID: 15277907
    [No Abstract]   [Full Text] [Related]  

  • 20. [Renal toxicity of sevoflurane].
    Monedero P
    Rev Esp Anestesiol Reanim; 1999; 46(6):233-5. PubMed ID: 10439641
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.